The nation of Zimbabwe has declined a major US healthcare agreement valued at $367m (£272m) over five years over the United States' insistence on confidential information.
The decision came to light following a government memo from December was disclosed, revealing that Head of State Emmerson Mnangagwa felt the agreement was "skewed".
A government spokesman has since clarified that the United States was demanding access to health data for scientific study and commercial purposes while was not willing to guarantee the benefits from any future treatments.
"We are forced to start the challenging and unfortunate task of winding down our health assistance in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont publicly.
The US Embassy indicated the US had donated over $1.9bn for health programmes to Zimbabwe during the past twenty years.
A doctors' association in Zimbabwe has urged more negotiations to reach a agreement suitable to all parties so the country's vital HIV treatment initiative can be sustained.
Broader Context
This rejection comes after a similar case in Kenya, where a high court suspended a similar health funding agreement after concerns were raised about the safety of citizens' medical information.
After returning to office recently, US President Donald Trump has slashed overseas assistance and closed the US Agency for International Development (USAID).
The agency had managed assistance for the American government, but Trump claimed its spending was "inefficient" and his administration was seeking direct bilateral agreements to enhance transparency and responsibility.
According to statements, 16 nations in Africa have so far agreed to similar health pacts, representing over $18.3bn in new funding.
Specifics of the Declined Deal
The funds for Zimbabwe was intended to gone towards "combating HIV/Aids, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We believe this collaboration could have provided significant advantages for the people of Zimbabwe, particularly the 1.2 million men, women and children currently on antiretroviral therapy through US-supported initiatives," Tremont added.
However, official spokesman Nick Mangwana maintained the proposed deal was "unfair".
"Our nation was requested to provide its biological resources and data over an extended period, with no corresponding guarantee of benefiting from any scientific breakthroughs – like vaccines, diagnostics, or treatments – that might result from that provided information," he stated.
"In essence, our country would provide the basic resources for medical research without any certainty that the final treatments would be available to our population if a new health crisis emerge."
Sovereignty and Global Health
Mangwana further pointed out that the American exit from the World Health Organization (WHO) and its pursuit of bilateral health agreements were undermining structures already established through the global health agency.
Mangwana gave as an example its Pathogen Access and Benefit Sharing framework designed to manage future pandemics.
"This system is designed to guarantee that when a nation contributes its samples, the benefits – including vaccines and treatments – are distributed fairly, not commercialised solely by those with the capability to develop them."
These objections over the US deal "must not be interpreted as opposition to America," he added.
"We welcome continued dialogue with our American counterparts on how subsequent collaboration might be structured in a way that respects the independence and dignity of both nations."
Medical Community Response
A leading public health body said it understood the official position, but urged that negotiations need to persist given that a large portion of the nation's HIV programmes were funded by international support.
"In cases where technical issues exist, such as those relating to information security or implementation frameworks, these can frequently be resolved via detailed discussion and mutually agreed protections," the group commented.
The situation emphasises the complex debate between accepting crucial foreign assistance and protecting national sovereignty in an increasingly data-driven world.